Home
About
Science
Solutions
Partners
Investors
News
News
August 12, 2019
Cellect Biotechnology Announces Positive Outcome From Safety Review Committee; Successfully Transplants 9th Clinical Trial Patient
July 9, 2019
Cellect Biotechnology and Washington University (WU) Finalize Accelerated Clinical Trial Agreement
May 21, 2019
Cellect Reports First Quarter 2019 Financial Results and Operations
May 16, 2019
Cellect Biotechnology Announces Receipt of Nasdaq Minimum Bid Price Notification
May 16, 2019
Cellect Biotechnology to Explore Strategic Alternatives to Maximize Shareholder Value
March 27, 2019
Cellect Announces Positive Phase I/II Mid-Study Results of Its ApoGraft™ Technology
March 11, 2019
Cellect Announces Positive Results From Cell2in Collaboration Showing Significant Improvement in Expansion Rate and Function of Stem Cells
February 5, 2019
Cellect Begins Collaboration with Washington University in Preparation for First U.S. Clinical Trial Using Cellect's ApoGraft™ for Bone Marrow Transplantations
January 28, 2019
Completion of Manufacturing of Clinical Grade FasL Enables Cellect to Expedite U.S. Clinical Programs into Multiple Studies
January 23, 2019
Cellect Biotechnology Reports Clinical and Regulatory Milestone Targets
December 17, 2018
KORIL Approves Cellect's Grant Application
November 13, 2018
Cellect Biotechnology Provides Corporate Update and Reports Third Quarter 2018 Financial Results
November 5, 2018
Cellect Receives Multiple Patent Grants
November 1, 2018
Cellect to Present Its Breakthrough Stem Cell Production Technology at the BIO-Europe
October 22, 2018
Cellect Announces a Major Technological Breakthrough for Industrialization of Apotainer™ Stem Cell Product Line
October 18, 2018
Positive Results of Orthopedic Treatment With the Use of ApoGraft™ Enriched Stem Cells Derived From Fat Tissues
October 15, 2018
Cellect Announces Positive Clinical Results
August 20, 2018
Cellect Receives Notice of Allowance for Stem Cell Selection Technology Patent in Korea
August 13, 2018
Cellect and Cell2in Launch Collaboration to Significantly Improve Stem Cell Selection and Expansion
August 9, 2018
Cellect Biotechnology Provides Corporate Update and Reports Second Quarter 2018 Financial Results
August 7, 2018
Cellect Granted Key European Patent for Its Stem Cell Selection Technology
July 9, 2018
Cellect Signed Strategic Agreement with Swiss Biotech Center (SBC)
July 5, 2018
Cellect Signs Collaboration Agreement With Dresden University denovoMATRIX Team
May 17, 2018
Cellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2018 Financial Results
May 10, 2018
Former GE Healthcare Executive to Join Cellect as Chief Business Officer
April 9, 2018
Cellect Announces a Major Milestone for Enabling Stem Cells Production
March 19, 2018
Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
January 29, 2018
Cellect Biotechnology Announces $4 Million Registered Direct Offering
January 16, 2018
Cellect Announces Opening of a Second Clinical Trial Site and Approval from Safety Board (DSMB) for Dose Escalation
January 4, 2018
Cellect Announces Breakthrough Clinical Results
November 22, 2017
Cellect Biotechnology Ltd Provides Corporate Update and Reports Third Quarter 2017 Financial Results
November 10, 2017
Cellect CEO, Dr. Shai Yarkoni Selected as Keynote Speaker at the 11th World Congress of Regenerative Medicine & Stem Cell in Singapore
October 31, 2017
Cellect Chosen Among Selected Global Leaders Presenting at Bio-Europe 2017 Conference Addressing over 3,800 Industry Specialists from Over 2,000 World Leading Companies
October 25, 2017
Cellect Announces a Major Breakthrough of its ApoGraft™ Technology: Reporting Today Positive Results from a 20 Patients Trial With Tel-Aviv Ichilov Medical Center
October 19, 2017
Cellect Appoints Dr. Ronit Bakimer-Kleiner as Chief Development Officer
September 7, 2017
Cellect Biotechnology Announces $4.3 Million Raise in a Registered Direct Offering
September 5, 2017
FDA Grants Orphan Drug Status to Cellect's ApoGraft™ for Acute GvHD and Chronic GvHD
September 1, 2017
Cellect Shares Will Be Traded From Next Week Exclusively on NASDAQ
August 21, 2017
Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2017 Financial Results
August 7, 2017
Cellect Engages Locust Walk to Support Business Development Activities for Cellect's ApoGraft™
June 14, 2017
Following the US, Cellect Receives Russian Patent Covering Any Device and Method Using Cellect's Flagship Technology - the ApoGraft™
June 12, 2017
Cellect Receives Notice of Allowance from the US Patent & Trademark Office
May 23, 2017
David Braun, Head of Merck Device Business (MD&S), Joins Cellect's Advisory Board
